Document is current
Any future updates will be listed below
-
Authors
Bindellini, Davide https://orcid.org/0009-0000-0758-5951
Michelet, Robin https://orcid.org/0000-0002-5485-607X
Aulin, Linda B. S. https://orcid.org/0000-0003-4840-5704
Melin, Johanna https://orcid.org/0000-0002-5463-8398
Neumann, Uta https://orcid.org/0000-0003-3892-0577
Blankenstein, Oliver https://orcid.org/0000-0003-1803-5589
Huisinga, Wilhelm https://orcid.org/0000-0002-5249-3914
Whitaker, Martin J. https://orcid.org/0000-0003-2388-4753
Ross, Richard https://orcid.org/0000-0001-9222-9678
Kloft, Charlotte
-
Funding
Funding for this research was provided by:
Freie Universität Berlin
- License Information
-
More Information
Article History
Received: 21 February 2024
Accepted: 30 June 2024
First Online: 8 July 2024
Declarations
:
: D.B., R.M., L.A. and M.J.W. have no conflict of interest. U.N. received a consultant and presentation fee from Diurnal Ltd., O.B. received a presentation fee from Diurnal Ltd., R.R. is a consultant to Neurocrine (Diurnal Ltd.). C.K. and W.H. report grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., Astra Zeneca, Boehringer Ingelheim Pharma GmbH & Co. K.G., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk, and Sanofi) for the PharMetrX PhD program. C.K. reports an additional grant from the Innovative Medicines Initiative-Joint Undertaking (‘DDMoRe’), grants from the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and from the European Commission within in the Horizon 2020 framework programme (“FAIR”), all outside the submitted work.
